Compare
Perspective Therapeutics, Inc. vs Arcturus Therapeutics Holdings Inc. vs Nature's Sunshine Products Inc vs Damora Therapeutics, Inc.
| Latest fiscal year | Perspective Therapeutics, Inc. CATX | Arcturus Therapeutics Holdings Inc. ARCT | Nature's Sunshine Products Inc NATR | Damora Therapeutics, Inc. DMRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $82.03M | $480.14M | n/a |
| Revenue growth (YoY) | n/a | -46.1% | +5.7% | n/a |
| Gross margin | n/a | n/a | 72.4% | n/a |
| Operating margin | n/a | -93.0% | 5.2% | n/a |
| Net margin | n/a | -80.2% | 4.3% | n/a |
| Net income | -$103.12M | -$65.78M | $20.45M | -$209.84M |
| EPS (Diluted) | -$1.40 | -$2.40 | $1.06 | $3.98 |
| Operating cash flow | -$82.48M | -$74.27M | $35.32M | -$6.73M |
| Free cash flow | -$95.23M | -$74.50M | $28.84M | n/a |
| Cash & equivalents | $30.63M | $230.91M | $93.89M | $257.62M |
| Total assets | $266.97M | $271.15M | $261.15M | $260.53M |
| Total liabilities | $59.94M | $57.16M | $99.59M | $20.15M |
| Shareholders' equity | $207.03M | $213.99M | $161.55M | $240.38M |
| Return on year-end equity | -49.8% | -30.7% | 12.7% | -87.3% |
| Shares outstanding | 74.34M | 28.41M | 17.51M | 1.60M |
Revenue, most recent five fiscal years
| Fiscal year | Perspective Therapeutics, Inc. | Arcturus Therapeutics Holdings Inc. | Nature's Sunshine Products Inc | Damora Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.43M Ended 2023-12-31 | $82.03M Ended 2025-12-31 | $480.14M Ended 2025-12-31 | n/a |
| 1 year earlier | $0 Ended 2022-12-31 | $152.31M Ended 2024-12-31 | $454.36M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $166.80M Ended 2023-12-31 | $445.32M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $206.00M Ended 2022-12-31 | $421.91M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $12.36M Ended 2021-12-31 | $444.08M Ended 2021-12-31 | n/a |